Skip to content

Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions

Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00814346
Enrollment
49
Registered
2008-12-24
Start date
2008-10-31
Completion date
2012-07-31
Last updated
2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Cognitive Impairment

Keywords

Mild Alzheimer's disease (AD) patients, Memory complaint patients with cognitive impairment (MC), Memory complaint patients cognitively normal (CNE)

Brief summary

The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). The first phase includes four weeks treatment with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18 FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU) period with EGb761® treatment in MC and CNE patients.

Interventions

Four weeks for AD patients, 18 months for MC and CNE patients

DRUGPlacebo

Placebo 1 tablet BID

Sponsors

Ipsen
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Group Specific Inclusion Criteria: Cognitively normal elderly (CNE) * Spontaneous memory complaint by patient, * Mini-Mental State Exam score ≥ 28. * Clinical Dementia Rating = 0. * No Diagnostic And Statistical Manual Of Mental Disorders, Fourth Edition (DSMIV) criteria for Dementia. Memory complaints (MC) : * Spontaneous memory complaint by patient * Mini-Mental State Exam score ≥ 25 * Clinical Dementia Rating 0.5. * No DSMIV criteria for Dementia. Mild Alzheimer's Disease (AD): * Mini Mental Status Examination (MMSE) between 20 and 28 (inclusive). * Clinical Dementia Rating ≥ 1.0 * DSMIV criteria for Dementia. * National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association(NINCDS/ADRDA) criteria for probable AD. * Newly diagnosed patients without treatment by Cholinesterase Inhibitors or Memantine. * ≥ 65 years of age, both sex * Geriatric Depression Scale (GDS) \< 15 * Informed consent signed by the patient or, if necessary by legal representative

Exclusion criteria

* Contraindication to Magnetic Resonance Imaging (MRI) and/or Positron-Emission Tomography (PET) scan * Forbidden Concomitant medications (Cholinesterase inhibitors and memantine, Specific psychoactive medications,e.g., neuroleptics, chronic anxiolytics including meprobamate, or sedative hypnotics other than benzodiazepines, Monoamine oxidase inhibitors (MAOIs) including selective MAOIs. Drugs acting on cerebral nervous system, Antidiabetes medications , Antioxidants medications, Medications known to interfere with cognitive evaluations * Significant neurological disease and psychiatric disorders/psychotic feature * Significant medical illness

Design outcomes

Primary

MeasureTime frameDescription
Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)From Baseline (Month 0) to Week 4 (Month 1) - Double blind phaseFollowing statistical parametric mapping (SPM) analyses were performed by the Commissariat à l'Energie Atomique (CEA): * The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only) * The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease. SUVBSA2 = \[Brain radioactivity (Bq/cc)\] / \[Injected dose (MBq)/BSA2\] x \[Blood glucose (g/l)\] BSA2(m\^2) = 0.007184 x Height (cm)\^0.35 x weight (kg)\^0.80 Standardized Uptake Value (SUV) Body Surface Area (BSA)

Secondary

MeasureTime frameDescription
Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 9CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).
Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 9The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By yes or no answers, scores permit to classify patients into groups of severely depressed (score of 21 to 30), moderately depressed (score of 11 to 20) and normal (score of 0 to10). It takes10 to 15 minutes to administer.
Change in Cognitive Tests-Verbal Fluency in MC and CNE GroupsFrom Baseline (Month 0) to Month 9Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A. Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names. Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.
Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 9MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 9Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 9Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy. The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)From Baseline (Month 0) to Month 9Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled. Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores. Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE GroupsFrom Baseline (Month 0) to Month 9Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory. Score range from 0(worst) to 75 (better).
Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE GroupsFrom Baseline (Month 0) to Month 9Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities. Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.
Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE GroupsFrom Baseline (Month 0) to Month 9TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement. First, in the TMT A, the subject has to connect numbers increasingly as fast as possible. The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.
Change in Brain Glucose Metabolism in the MC and CNE GroupsFrom Baseline (Month 0) to Month 18Brain glucose metabolism measured by 18FDG PET SUVBSA2 = \[Brain radioactivity (Bq/cc)\] / \[Injected dose (MBq)/BSA2\] x \[Blood glucose (g/l)\] BSA2(m\^2) = 0.007184 x Height (cm)\^0.35 x weight (kg)\^0.80
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)At Month 9The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.
Change in Cognitive Tests-CDR Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 18CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)
Change in Cognitive Tests-GDS Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 18The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By yes or no answers, scores permit to classify patients into groups of severely depressed (score of 21 to 30), moderately depressed (score of 11 to 20) and normal (score of 0 to10). It takes10 to 15 minutes to administer.
Change in Cognitive Tests-MMSE Score in MC and CNE GroupsFrom Baseline (Month 0) to Month 18MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRTFrom Baseline (Month 0) to Month 18Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled. Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores. Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).
Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE GroupsFrom Baseline (Month 0) to Month 18Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities. Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.
Change in Cognitive Tests-Time to Perform TMT in MC and CNE GroupsFrom Baseline (Month 0) to Month 18TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement. First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.
Incidence of Adverse Events (AEs)Up to Month 18The relationship of an adverse event to the study medication will be classified according to the following criteria: Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.
Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeFrom Baseline (Month 0) to Month 18Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)At Month 9The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria. National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)

Countries

France

Participant flow

Pre-assignment details

A total of 63 participants were screened of which 49 subjects were randomised to either EGb761 and Placebo treatment groups (double-blind period). The 49 randomised subjects consisted of three groups of elderly subjects: Cognitively normal elderly (CNE), Memory Complaint (MC) and Alzheimer's Disease (AD).

Participants by arm

ArmCount
EGb761 120 mg
EGb761 120 mg tablet twice a day for 4 weeks (Double-blind phase) for CNE, MC, and AD patients and 17 months (Open phase) for CNE and MC patients
23
Placebo
Placebo 1 tablet twice a day for 4 weeks CNE, MC, and AD patients
26
Total49

Withdrawals & dropouts

PeriodReasonFG000FG001
Double-blind Phase (4 Weeks)Adverse Event01
Double-blind Phase (4 Weeks)Not otherwise specified02
Open Phase (17 Months)Adverse Event50
Open Phase (17 Months)Consent20
Open Phase (17 Months)Lost to Follow-up20
Open Phase (17 Months)Not otherwise specified10

Baseline characteristics

CharacteristicPlaceboTotalEGb761 120 mg
Age, Continuous76.6 years
STANDARD_DEVIATION 5.3
75.85 years
STANDARD_DEVIATION 5.25
75.1 years
STANDARD_DEVIATION 6.2
Body Mass Index (BMI)25.03 kg/m^2
STANDARD_DEVIATION 4.4
24.76 kg/m^2
STANDARD_DEVIATION 4.43
24.49 kg/m^2
STANDARD_DEVIATION 4.46
Educational Level
Level 1: Primary only
0 participants1 participants1 participants
Educational Level
Level 2: School certificate
5 participants7 participants2 participants
Educational Level
Level 3: Completed secondary
6 participants9 participants3 participants
Educational Level
Level 4: University
15 participants32 participants17 participants
Sex: Female, Male
Female
17 Participants32 Participants15 Participants
Sex: Female, Male
Male
9 Participants17 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
5 / 239 / 2623 / 41
serious
Total, serious adverse events
1 / 230 / 266 / 41

Outcome results

Primary

Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)

Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l'Energie Atomique (CEA): * The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only) * The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease. SUVBSA2 = \[Brain radioactivity (Bq/cc)\] / \[Injected dose (MBq)/BSA2\] x \[Blood glucose (g/l)\] BSA2(m\^2) = 0.007184 x Height (cm)\^0.35 x weight (kg)\^0.80 Standardized Uptake Value (SUV) Body Surface Area (BSA)

Time frame: From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase

Population: Intention to treat (ITT) population: All treated CNE and MC patients

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left globus pallidus-4.33 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right cerebral cortex-7.49 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right caudate nucleus-1.59 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right thalamus-7.40 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right globus pallidus-2.04 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left thalamus-8.46 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right ventral striatum-7.08 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left caudate nucleus-0.68 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Cerebellum-3.40 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left putamen nucleus-1.91 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right putamen nucleus-6.31 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left ventral striatum1.49 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left cerebral cortex-8.56 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left putamen nucleus-0.19 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left globus pallidus-1.26 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left cerebral cortex2.25 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right globus pallidus-1.72 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right cerebral cortex0.19 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Cerebellum-1.07 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left caudate nucleus4.60 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left ventral striatum-7.29 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right thalamus-2.05 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right putamen nucleus-2.73 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right caudate nucleus-0.66 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left thalamus-0.06 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right ventral striatum-0.76 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left thalamus-2.09 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right thalamus-3.87 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Cerebellum-7.58 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left cerebral cortex0.44 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left caudate nucleus2.16 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left putamen nucleus2.15 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left ventral striatum2.37 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left globus pallidus-7.75 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right cerebral cortex-7.11 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right caudate nucleus-9.21 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right putamen nucleus-8.84 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right ventral striatum-8.21 SUVBSA2
EGb761 120 mg (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right globus pallidus-5.99 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right caudate nucleus-6.45 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left putamen nucleus-6.20 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left caudate nucleus3.27 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Cerebellum-3.09 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right putamen nucleus-5.36 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left thalamus-6.19 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left globus pallidus-8.72 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right globus pallidus-1.24 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right ventral striatum-0.59 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right thalamus-7.72 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Right cerebral cortex-6.59 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left ventral striatum-4.62 SUVBSA2
Placebo (MC)Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)Left cerebral cortex-0.32 SUVBSA2
Secondary

Change in Brain Glucose Metabolism in the MC and CNE Groups

Brain glucose metabolism measured by 18FDG PET SUVBSA2 = \[Brain radioactivity (Bq/cc)\] / \[Injected dose (MBq)/BSA2\] x \[Blood glucose (g/l)\] BSA2(m\^2) = 0.007184 x Height (cm)\^0.35 x weight (kg)\^0.80

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft thalamus-0.03 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight cerebral cortex-0.07 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft putamen nucleus0.07 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight thalamus0.04 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft cerebral cortex-0.06 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight caudate nucleus0.03 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft ventral striatum-0.05 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight putamen nucleus0.04 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft caudate nucleus-0.11 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight ventral striatum0.01 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft globus pallidus0.00 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight globus pallidus0.06 SUVBSA2
EGb 120 mg (Open Phase - CNE)Change in Brain Glucose Metabolism in the MC and CNE GroupsCerebellum-0.07 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight globus pallidus0.06 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsCerebellum0 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft cerebral cortex-0.08 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft thalamus-0.02 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft caudate nucleus-0.01 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft putamen nucleus0.00 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft ventral striatum-0.09 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsLeft globus pallidus-0.01 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight cerebral cortex-0.06 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight thalamus-0.00 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight caudate nucleus-0.02 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight putamen nucleus0.02 SUVBSA2
EGb 120 mg (Open Phase - MC)Change in Brain Glucose Metabolism in the MC and CNE GroupsRight ventral striatum-0.05 SUVBSA2
Secondary

Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size

Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft thalamus145.20 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight cerebral cortex5853.00 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft putamen nucleus-17.14 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight thalamus144.83 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft cerebral cortex5765.50 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight caudate nucleus228.74 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft ventral striatum65.26 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight putamen nucleus8.36 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft caudate nucleus154.68 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight ventral striatum65.15 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft globus pallidus104.75 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight globus pallidus84.68 mm3
EGb 120 mg (Open Phase - CNE)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeCerebellum6454.00 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight globus pallidus64.82 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeCerebellum6168.50 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft cerebral cortex32428.00 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft thalamus24.57 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft caudate nucleus140.97 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft putamen nucleus4.00 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft ventral striatum81.56 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeLeft globus pallidus50.66 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight cerebral cortex38955.50 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight thalamus14.90 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight caudate nucleus303.66 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight putamen nucleus-78.94 mm3
EGb 120 mg (Open Phase - MC)Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel SizeRight ventral striatum70.85 mm3
Secondary

Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups

Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory. Score range from 0(worst) to 75 (better).

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups0.00 Age adjusted score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups0.00 Age adjusted score
Secondary

Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups

Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory. Score range from 0(worst) to 75 (better).

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups1.00 Age adjusted score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups-1.00 Age adjusted score
Secondary

Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups

Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities. Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups1.00 Age adjusted score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups1.50 Age adjusted score
Secondary

Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups

Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities. Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups1.00 Age adjusted score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups1.00 Age adjusted score
Secondary

Change in Cognitive Tests-CDR Score in MC and CNE Groups

CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-CDR Score in MC and CNE Groups0.00 CDR overall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-CDR Score in MC and CNE Groups0.00 CDR overall score
Secondary

Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups

CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups0.00 CDR overall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups0.00 CDR overall score
Secondary

Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups

Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups0.00 Clock drawing test score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups0.00 Clock drawing test score
Secondary

Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups

Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups0.00 Clock drawing test score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups0.00 Clock drawing test score
Secondary

Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups

Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy. The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups0.00 Cube drawing test score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups0.00 Cube drawing test score
Secondary

Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups

Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy. The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups0.00 Cube drawing test score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups0.00 Cube drawing test score
Secondary

Change in Cognitive Tests-GDS Score in MC and CNE Groups

The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By yes or no answers, scores permit to classify patients into groups of severely depressed (score of 21 to 30), moderately depressed (score of 11 to 20) and normal (score of 0 to10). It takes10 to 15 minutes to administer.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-GDS Score in MC and CNE Groups1.00 GDS Score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-GDS Score in MC and CNE Groups0.50 GDS Score
Secondary

Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups

The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By yes or no answers, scores permit to classify patients into groups of severely depressed (score of 21 to 30), moderately depressed (score of 11 to 20) and normal (score of 0 to10). It takes10 to 15 minutes to administer.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups-2.00 GDS Score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups0.00 GDS Score
Secondary

Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT

Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled. Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores. Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRTTotal Immediate Recall Score of FCSRT2.00 Recall score
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRTTotal Delayed Recall Score of FCSRT0.00 Recall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRTTotal Immediate Recall Score of FCSRT1.50 Recall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRTTotal Delayed Recall Score of FCSRT0.00 Recall score
Secondary

Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)

Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled. Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores. Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)Total Immediate Recall Score1.00 Recall score
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)Total Delayed Recall Score0.00 Recall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)Total Immediate Recall Score0.00 Recall score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)Total Delayed Recall Score0.00 Recall score
Secondary

Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups

MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups0.00 MMSE Score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups0.00 MMSE Score
Secondary

Change in Cognitive Tests-MMSE Score in MC and CNE Groups

MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-MMSE Score in MC and CNE Groups0.00 MMSE Score
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-MMSE Score in MC and CNE Groups0.00 MMSE Score
Secondary

Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups

TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement. First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Time to Perform TMT in MC and CNE GroupsTask A (N=18,12)-3.00 Seconds
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Time to Perform TMT in MC and CNE GroupsTask B (N=18,11)-4.50 Seconds
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Time to Perform TMT in MC and CNE GroupsTask A (N=18,12)-1.00 Seconds
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Time to Perform TMT in MC and CNE GroupsTask B (N=18,11)-9.00 Seconds
Secondary

Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups

TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement. First, in the TMT A, the subject has to connect numbers increasingly as fast as possible. The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE GroupsTask A (N=17,18)2.00 Seconds
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE GroupsTask B (N=17,16)0.00 Seconds
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE GroupsTask A (N=17,18)2.50 Seconds
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE GroupsTask B (N=17,16)-5.50 Seconds
Secondary

Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups

Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A. Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names. Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.

Time frame: From Baseline (Month 0) to Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Verbal Fluency in MC and CNE GroupsCategorical verbal fluency-1.50 Number of good answers
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Verbal Fluency in MC and CNE GroupsLexical verbal fluency-1.00 Number of good answers
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Verbal Fluency in MC and CNE GroupsCategorical verbal fluency-2.00 Number of good answers
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Verbal Fluency in MC and CNE GroupsLexical verbal fluency2.00 Number of good answers
Secondary

Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups

Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A. Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names. Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.

Time frame: From Baseline (Month 0) to Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureGroupValue (MEDIAN)
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Verbal Fluency in MC and CNE Groupscategorical verbal fluency-1.00 Number of good answers
EGb 120 mg (Open Phase - CNE)Change in Cognitive Tests-Verbal Fluency in MC and CNE Groupslexical verbal fluency-1.00 Number of good answers
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Verbal Fluency in MC and CNE Groupscategorical verbal fluency1.00 Number of good answers
EGb 120 mg (Open Phase - MC)Change in Cognitive Tests-Verbal Fluency in MC and CNE Groupslexical verbal fluency1.50 Number of good answers
Secondary

Incidence of Adverse Events (AEs)

The relationship of an adverse event to the study medication will be classified according to the following criteria: Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.

Time frame: Up to Month 18

Population: Safety population. CNE patients withdrew during the double-blind phase and were also not included in the safety population for open phase (17 months).

ArmMeasureGroupValue (NUMBER)
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Any Treatment Emergent5 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Causality of Non Related TEAEs4 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Causality of Related TEAEs1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Any Adverse Events5 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Causality and Intensity0 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)TEAES Leading to Death0 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one related & severe0 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Intensity of Severe Treatment Emergent AEs (TEAEs)1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Serious AEs (SAEs)1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one related & moderate0 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one not related & mild3 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)TEAEs leading to withdrawal1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Non SAEs5 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one related & mild1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Intensity of mild TEAEs4 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)Intensity of moderate TEAEs2 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one not related & severe1 participants
EGb 120 mg (Open Phase - CNE)Incidence of Adverse Events (AEs)At least one not related & moderate2 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Intensity of moderate TEAEs4 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one not related & moderate3 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one not related & mild3 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Intensity of mild TEAEs5 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)TEAEs leading to withdrawal2 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)TEAES Leading to Death0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Serious AEs (SAEs)0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Causality of Related TEAEs2 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Non SAEs9 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Any Treatment Emergent8 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Causality of Non Related TEAEs6 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Causality and Intensity0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one related & severe0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Intensity of Severe Treatment Emergent AEs (TEAEs)0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one related & moderate1 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one not related & severe0 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)Any Adverse Events9 participants
EGb 120 mg (Open Phase - MC)Incidence of Adverse Events (AEs)At least one related & mild2 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one related & mild2 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Any Adverse Events25 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Any Treatment Emergent25 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Intensity of Severe Treatment Emergent AEs (TEAEs)6 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Intensity of moderate TEAEs14 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Intensity of mild TEAEs20 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Causality of Related TEAEs3 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Causality of Non Related TEAEs25 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one related & severe0 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one related & moderate1 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Causality and Intensity0 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one not related & severe6 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one not related & moderate14 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)TEAES Leading to Death0 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)At least one not related & mild20 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Non SAEs23 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)TEAEs leading to withdrawal4 participants
EGb761 120 mg (MC)Incidence of Adverse Events (AEs)Serious AEs (SAEs)6 participants
Secondary

Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)

The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.

Time frame: At Month 9

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (NUMBER)
EGb 120 mg (Open Phase - CNE)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)0 participants
EGb 120 mg (Open Phase - MC)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)1 participants
Secondary

Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)

The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.

Time frame: At Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (NUMBER)
EGb 120 mg (Open Phase - CNE)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)0 participants
EGb 120 mg (Open Phase - MC)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)0 participants
Secondary

Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)

The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.

Time frame: At Month 18

Population: ITT population. N=Number of subjects with assessment.

ArmMeasureValue (NUMBER)
EGb 120 mg (Open Phase - CNE)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)0 participants
EGb 120 mg (Open Phase - MC)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)0 participants
Secondary

Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)

The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria. National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)

Time frame: At Month 9

Population: ITT population. N=Number of subjects with assessment

ArmMeasureValue (NUMBER)
EGb 120 mg (Open Phase - CNE)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)0 participants
EGb 120 mg (Open Phase - MC)Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)1 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026